Cardiogenic Pulmonary Edema in Emergency Medicine.

IF 1.8 Q3 RESPIRATORY SYSTEM
Christian Zanza, Francesco Saglietti, Manfredi Tesauro, Yaroslava Longhitano, Gabriele Savioli, Mario Giosuè Balzanelli, Tatsiana Romenskaya, Luigi Cofone, Ivano Pindinello, Giulia Racca, Fabrizio Racca
{"title":"Cardiogenic Pulmonary Edema in Emergency Medicine.","authors":"Christian Zanza,&nbsp;Francesco Saglietti,&nbsp;Manfredi Tesauro,&nbsp;Yaroslava Longhitano,&nbsp;Gabriele Savioli,&nbsp;Mario Giosuè Balzanelli,&nbsp;Tatsiana Romenskaya,&nbsp;Luigi Cofone,&nbsp;Ivano Pindinello,&nbsp;Giulia Racca,&nbsp;Fabrizio Racca","doi":"10.3390/arm91050034","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiogenic pulmonary edema (CPE) is characterized by the development of acute respiratory failure associated with the accumulation of fluid in the lung's alveolar spaces due to an elevated cardiac filling pressure. All cardiac diseases, characterized by an increasing pressure in the left side of the heart, can cause CPE. High capillary pressure for an extended period can also cause barrier disruption, which implies increased permeability and fluid transfer into the alveoli, leading to edema and atelectasis. The breakdown of the alveolar-epithelial barrier is a consequence of multiple factors that include dysregulated inflammation, intense leukocyte infiltration, activation of procoagulant processes, cell death, and mechanical stretch. Reactive oxygen and nitrogen species (RONS) can modify or damage ion channels, such as epithelial sodium channels, which alters fluid balance. Some studies claim that these patients may have higher levels of surfactant protein B in the bloodstream. The correct approach to patients with CPE should include a detailed medical history and a physical examination to evaluate signs and symptoms of CPE as well as potential causes. Second-level diagnostic tests, such as pulmonary ultrasound, natriuretic peptide level, chest radiograph, and echocardiogram, should occur in the meantime. The identification of the specific CPE phenotype is essential to set the most appropriate therapy for these patients. Non-invasive ventilation (NIV) should be considered early in the treatment of this disease. Diuretics and vasodilators are used for pulmonary congestion. Hypoperfusion requires treatment with inotropes and occasionally vasopressors. Patients with persistent symptoms and diuretic resistance might benefit from additional approaches (i.e., beta-agonists and pentoxifylline). This paper reviews the pathophysiology, clinical presentation, and management of CPE.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 5","pages":"445-463"},"PeriodicalIF":1.8000,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604083/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/arm91050034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiogenic pulmonary edema (CPE) is characterized by the development of acute respiratory failure associated with the accumulation of fluid in the lung's alveolar spaces due to an elevated cardiac filling pressure. All cardiac diseases, characterized by an increasing pressure in the left side of the heart, can cause CPE. High capillary pressure for an extended period can also cause barrier disruption, which implies increased permeability and fluid transfer into the alveoli, leading to edema and atelectasis. The breakdown of the alveolar-epithelial barrier is a consequence of multiple factors that include dysregulated inflammation, intense leukocyte infiltration, activation of procoagulant processes, cell death, and mechanical stretch. Reactive oxygen and nitrogen species (RONS) can modify or damage ion channels, such as epithelial sodium channels, which alters fluid balance. Some studies claim that these patients may have higher levels of surfactant protein B in the bloodstream. The correct approach to patients with CPE should include a detailed medical history and a physical examination to evaluate signs and symptoms of CPE as well as potential causes. Second-level diagnostic tests, such as pulmonary ultrasound, natriuretic peptide level, chest radiograph, and echocardiogram, should occur in the meantime. The identification of the specific CPE phenotype is essential to set the most appropriate therapy for these patients. Non-invasive ventilation (NIV) should be considered early in the treatment of this disease. Diuretics and vasodilators are used for pulmonary congestion. Hypoperfusion requires treatment with inotropes and occasionally vasopressors. Patients with persistent symptoms and diuretic resistance might benefit from additional approaches (i.e., beta-agonists and pentoxifylline). This paper reviews the pathophysiology, clinical presentation, and management of CPE.

Abstract Image

Abstract Image

Abstract Image

急诊医学中的心源性肺水肿。
心源性肺水肿(CPE)的特征是由于心脏充盈压力升高而导致肺泡空间中的液体积聚,从而导致急性呼吸衰竭。所有以心脏左侧压力增加为特征的心脏疾病都会导致CPE。长时间的高毛细管压力也会导致屏障破坏,这意味着渗透性增加,液体转移到肺泡中,导致水肿和肺不张。肺泡上皮屏障的破坏是多种因素的结果,包括失调的炎症、强烈的白细胞浸润、促凝过程的激活、细胞死亡和机械拉伸。活性氧和氮物质(RONS)可以改变或破坏离子通道,如上皮钠通道,从而改变液体平衡。一些研究声称,这些患者血液中的表面活性剂蛋白B水平可能更高。CPE患者的正确治疗方法应包括详细的病史和体检,以评估CPE的体征和症状以及潜在原因。二级诊断检查,如肺部超声、利钠肽水平、胸部X线片和超声心动图,应同时进行。特异性CPE表型的鉴定对于为这些患者设定最合适的治疗至关重要。无创通气(NIV)应在治疗该疾病的早期考虑。利尿剂和血管舒张剂用于治疗肺充血。低灌注需要使用止痛药治疗,偶尔也需要使用血管升压药。具有持续症状和利尿剂耐药性的患者可能受益于其他方法(即β激动剂和己酮可可碱)。本文综述CPE的病理生理学、临床表现和治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in respiratory medicine
Advances in respiratory medicine RESPIRATORY SYSTEM-
CiteScore
2.60
自引率
0.00%
发文量
90
期刊介绍: "Advances in Respiratory Medicine" is a new international title for "Pneumonologia i Alergologia Polska", edited bimonthly and addressed to respiratory professionals. The Journal contains peer-reviewed original research papers, short communications, case-reports, recommendations of the Polish Respiratory Society concerning the diagnosis and treatment of lung diseases, editorials, postgraduate education articles, letters and book reviews in the field of pneumonology, allergology, oncology, immunology and infectious diseases. "Advances in Respiratory Medicine" is an open access, official journal of Polish Society of Lung Diseases, Polish Society of Allergology and National Research Institute of Tuberculosis and Lung Diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信